Options market sees Celladon heart drug as all-or-nothing bet

By Saqib Iqbal Ahmed NEW YORK (Reuters) - Celladon Corp's shares could either double in value or collapse over the next four weeks after the drug developer announces results from a heart failure gene therapy trial, options data shows. Later this month, Celladon is expected to report results from a mid-stage study of Mydicar, its experimental gene therapy for advanced heart failure, a condition in which the heart muscle cannot pump enough blood to meet the body's needs.



via Health News Headlines - Yahoo News http://ift.tt/1G1XcH1